Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
Vijay Ramakrishnan(Mayo Clinic in Arizona), Shaji Kumar(Mayo Clinic in Arizona)
Cited by 24
Related Papers
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
|Mayo Clinic Proceedings|2009|625
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
|Haematologica|2019|36
Three‐dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma
|American Journal of Hematology|2024|8